Navigating lung nodules for resection using a new mapping technique
Artificial Intelligence Pulmonary Watershed Terrain Navigation System for Lung Nodule Localization and Lung Function Preservation
This study is testing a new way to locate small lung nodules during surgery to see if it helps patients with early-stage lung cancer recover faster and have better outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Guangdong Provincial People's Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06404164 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates a novel technique for localizing small pulmonary nodules using a method called watershed analysis, which allows for wedge resection without cutting blood vessels. The approach aims to reduce the need for CT-guided positioning, thereby saving costs and time in the operating room. By minimizing damage to lung tissue, the technique preserves pulmonary function and enables quicker patient recovery, with an average discharge time of three days post-operation. The study focuses on patients with early-stage non-small cell lung cancer (NSCLC) and aims to improve surgical outcomes.
Who should consider this trial
Good fit: Ideal candidates include patients with small, clinically resectable lung nodules located in the peripheral areas of the lung, specifically those classified as stage IA1 or IA2 NSCLC.
Not a fit: Patients with chronic lung diseases or those requiring extended resections may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to safer and more efficient lung nodule resections, improving recovery times and preserving lung function.
How similar studies have performed: While this approach is innovative, similar techniques in lung nodule localization have shown promise in other studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. \<1cm CTR≤0.75; \<1.5cm CTR≤0.5; \<2cm CTR≤0.25 Lung nodules 2. The tumor center is located in the peripheral 2/3 area of the lung field 3. Preoperative analysis and planning of watershed by 3D reconstruction 4. Clinically assessed as cT1aN0M0 stage IA1/cT1bN0M0 stage IA2 (eighth edition), clinically resectable Exclusion Criteria: 1. No surgical video, no postoperative gross specimen and related distance measurement records 2. The incision edge does not exceed the target nodule diameter from the nodule edge 3. The resection range exceeds 50% of the preoperative planning 4. Postoperative pathological staging non-pT1aN0M0 IA1 stage/pT1bN0M0 IA2 stage (eighth edition) 5. Any situation where the investigator feels the need for extended resection 6. Patients with chronic diseases (such as COPD, pulmonary fibrosis, silicosis) that can cause loss of lung function in patients at risk of progression or potential progression
Where this trial is running
Guangzhou, Guangdong
- Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: WenZhao Zhong
- Email: 13609777314@163.com
- Phone: +86-13609777314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.